Dianthus Therapeutics Inc. (DNTH)
Dianthus Therapeutics: The C1s Shakeout Strengthens The Bull Case
Dianthus Therapeutics is building a neuromuscular franchise around claseprubart, differentiated by clinical profile and financial independence. DNTH holds ~$1.2B in cash and investments, supporting multiple late-stage programs and reducing funding event risk through 2030. Claseprubart's dosing convenience, pathway selectivity, and strong early data set it apart amid evolving competitive dynamics, especially after Sanofi's setback.
Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.9 per share versus the Zacks Consensus Estimate of a loss of $0.93. This compares to a loss of $0.88 per share a year ago.
DNTH Shares Surge 89% Over the Past Six Months: What's Driving It?
Dianthus Therapeutics stock climbs 89% in six months as claseprubart advances across key autoimmune studies. Strong cash position supports development into 2030.
Dianthus Therapeutics, Inc. (DNTH) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Dianthus Therapeutics, Inc. (DNTH) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win
Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Lags Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $1.17. This compares to a loss of $0.82 per share a year ago.
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength?
Dianthus Therapeutics, Inc. (DNTH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Dianthus Therapeutics (NASDAQ:DNTH) CAO Sells $3,559,646.18 in Stock
Dianthus Therapeutics, Inc. (NASDAQ: DNTH - Get Free Report) CAO Edward Carr sold 43,682 shares of the business's stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $81.49, for a total value of $3,559,646.18. The sale was disclosed in a document filed with the Securities and Exchange Commission,
Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $2,756,468.40 in Stock
Dianthus Therapeutics, Inc. (NASDAQ: DNTH - Get Free Report) EVP Simrat Randhawa sold 33,830 shares of the firm's stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $81.48, for a total transaction of $2,756,468.40. The transaction was disclosed in a legal filing with the Securities and Exchange Commission,
Dianthus Therapeutics (NASDAQ:DNTH) CEO Sells $10,016,587.82 in Stock
Dianthus Therapeutics, Inc. (NASDAQ: DNTH - Get Free Report) CEO Marino Garcia sold 122,918 shares of Dianthus Therapeutics stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $81.49, for a total transaction of $10,016,587.82. The transaction was disclosed in a legal filing with the SEC, which
Dianthus Therapeutics: Go Decision For CIDP Program Warrants Continued Buy Rating
Dianthus Therapeutics, Inc. is maintained at a Buy rating, supported by strong clinical progress and a 174.53% stock gain since the last update. Claseprubart delivered statistically significant MG-ADL improvements in phase 2 Myasthenia Gravis and is advancing to phase 3, with topline data expected in 2H 2028. An early "GO decision" for the phase 3 CAPTIVATE trial in CIDP, driven by positive interim response rates, sets up a key DNTH catalyst with top-line data release update year-end 2026.
Dianthus Therapeutics, Inc. (DNTH) Discusses Interim Responder Analysis and Early Go Decision for CAPTIVATE Trial in CIDP Transcript
Dianthus Therapeutics, Inc. (DNTH) Discusses Interim Responder Analysis and Early Go Decision for CAPTIVATE Trial in CIDP Transcript
